WEBULL
WebtradeDownload

Vertex Pharmaceuticals (VRTX) Stock Could Stay Below Fair Value Despite Its 173% Run

Simply Wall St · 4d ago

Vertex Pharmaceuticals has delivered strong long term gains for shareholders, and the question now is whether the current US$529.69 share price is still aligned with the cash flows the business can generate. With the stock moving on both long run performance and fresh drug news, the focus turns to what its cash flow profile really supports.

  • The stock is up 172.7% over 5 years, which puts a lot of past optimism and future cash flow expectations on the line for anyone considering Vertex Pharmaceuticals today.
  • Positive Phase 3 results for povetacicept in IgA nephropathy and an FDA target action date in late 2026 may support expectations for future cash generation and influence how investors think about the timing of those cash flows.
  • If you'd rather focus on earnings, this one's for you. See why Vertex Pharmaceuticals's 30.5x P/E tells a different valuation story.

The issue now is whether Vertex Pharmaceuticals' current market price is justified by the cash flows implied by its Discounted Cash Flow (DCF) intrinsic value estimate.

If you want a second reference point alongside Vertex Pharmaceuticals, a focused stock screen built around 32 resilient stocks with low risk scores can be a useful starting list for further research.

Is Vertex Pharmaceuticals Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here takes Vertex Pharmaceuticals' future free cash flows and discounts them back to today. The latest twelve month Free Cash Flow sits at about $3.8b, and the projections used in the model assume growing cash generation over the coming years rather than a shrinking profile.

Analysts and internal estimates feed into this DCF with higher forecast free cash flow by 2030 and then slower growth after that, which is typical once a company is expected to be more mature. The projections put Vertex Pharmaceuticals' estimated intrinsic value substantially above the current share price of $529.69. Because the positive Phase 3 RAINIER results for povetacicept raise expectations for future treatments but still leave execution and regulatory risks on the table, the gap between the DCF value and the market price can reflect both growth hopes and a risk discount that investors are keeping in place. Find out what Vertex Pharmaceuticals could be worth using our Discounted Cash Flow (DCF) estimate.

The Vertex Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Vertex Pharmaceuticals pick up where the DCF puzzle leaves off by spelling out which paths for revenue growth, profitability and earnings would need to play out for the stock to be priced materially higher or lower than it is today, using the Community page as the home for those scenarios. Rather than leaning on a single multiple or model line, each framework lays out the assumptions behind its view of fair value so you can compare them with reported numbers over time.

The community is split between seeing Vertex Pharmaceuticals as a multi pillar rare disease platform still underpriced on its pipeline and a premium biotech where rich expectations already crowd the upside.

Bull case: 7% undervalued

"Analysts expect Vertex Pharmaceuticals to expand beyond cystic fibrosis into five commercial pillars, with renal disease, endocrinology, hematology, pain and type 1 diabetes collectively supporting a more balanced revenue mix over time..."

Discover why this Narrative puts Vertex Pharmaceuticals at 7% undervalued.

Bear case: 23% overvalued

"The numbers on guidance, acquisitions, and pipeline scale imply a share price that already bakes in successful diversification beyond cystic fibrosis and strong long term execution, leaving limited room for disappointment..."

Explore why this Narrative puts Vertex Pharmaceuticals at 23% overvalued.

One more question for Vertex Pharmaceuticals that sits beyond the share price

Cash flows tell you what Vertex Pharmaceuticals might be worth, but the real story also depends on who is steering the ship, how their priorities are set and what they get rewarded for. See who runs Vertex Pharmaceuticals and how they are paid.